Nerve irritation
Cancer: As seen in Figure 2, co-occurrences of GLP-1 and GIP receptor agonists and cancer have increased in recent years, particularly in 2023
For more information, please visit: Disclaimer This report was prepared by the Evidence Development and Standards branch at Health Quality Ontario or one of its research partners for the Ontario Health Technology Advisory Committee and was developed from analysis, interpretation, and comparison of scientific research
Reconstituted: Refrigerate at 28 C (35.646.4 F)
Incidences of other toxicities were comparable across the three treatment groups in DURATION-8 (exenatide plus dapagliflozin, exenatide alone, and dapagliflozin alone, respectively), including pancreatitis (1.3%, 0.4%, and 0%), volume depletion (1.3%, 0.4%, and 2.1%), gastrointestinal events (20.8%, 23.9%, and 16.3%), and genital infections (5.2%, 2.2%, and 7.7%) [36]